Corporacion Parc Tauli   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (1986)

Organization Overview

First Clinical Trial
2005
NCT00917592
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Antonio Giménez Gaibar | Corporacion Parc Tauli | Corporación Parc Taulí | Corporacio Parc Tauli | CORPORACIO SANITARIA PARC TAULI | Corporació Sanitaria Parc Tauli | Corporació Sanitaria Parc Taulí | Corporacio Sanitària Parc Taulí | Eduardo Arrea Salto | Elena Gonzalez Canas | Hospital Parc Taulí, Sabadell | Hospital Universitari Parc Taulí | Kerbi Alejandro Guevara-Noriega | Marta Camats Terre | Parc Tauli Hospital | Parc Tauli Hospital from Sabadell (Barcelona). Spain. | Parc Tauli Sabadell Hospital Universitari - Sabadell | Parc Tauli University Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Colonic Neoplasms (Phase 4)

Cystic Fibrosis (Phase 2)

Diabetes Complications (Phase 4)

Diabetic Neuropathies (Phase 4)

Diverticulitis (Phase 4)

Fibrosis (Phase 2)

Hip Fractures (Phase 4)

Neoplasm Metastasis (Phase 4)

Neoplasms, Second Primary (Phase 4)

Ovarian Neoplasms (Phase 2)

Prader-Willi Syndrome (Phase 4)

Prostatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 3)

Recurrence (Phase 3)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 37